Basilea Pharmaceutica 주식 가격. 0QNA - 주식 시세, 차트, 과거 거래, 주식 채팅, 재무.

개인 투자자를 위한 전문가급 도구.

프리미엄

가격

46.20

매수가

45.05

매도가

47.35

거래량

505

0.00 일간 변동폭 0.00

46.20 52주 범위 46.20

market_cap

554.492M

전일 종가

46.20

개장가

최근 거래 시간

40.1

(O)

마지막 거래 시간

재정 규모

VWAP

평균 볼륨(3m)

2,720

발행 주식

12,002,000

배당수익률

주가수익률

60.67

주당순이익(EPS)

0.87

매출

150.28M

순이익

10.45M

섹터

Pharmaceutical Preparations

산업

Pharmaceutical Preparations

웹사이트

www.basilea.com

본부

Basel, Che

설립됨

Basilea Pharmaceutica Ag is listed in the Pharmaceutical Preparations sector of the 런던증권거래소 with ticker 0QNA. The last closing price for Basilea Pharmaceutica was CHF46.20. Over the last year, Basilea Pharmaceutica shares have traded in a share price range of CHF 46.20 to CHF 46.20.

Basilea Pharmaceutica currently has 12,002,000 shares in issue. The market capitalisation of Basilea Pharmaceutica is CHF554.49 million. Basilea Pharmaceutica has a price to earnings ratio (PE ratio) of 60.67.

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year Allschwil, Switzerland, October 10, 2024 Basilea...

Starke Cresemba® (Isavuconazol)-Umsätze in Asien-Pazifik und China lösen vierte Meilensteinzahlung für diese Region in diesem Jahr an Basilea aus

Starke Cresemba® (Isavuconazol)-Umsätze in Asien-Pazifik und China lösen vierte Meilensteinzahlung für diese Region in diesem Jahr an Basilea aus Allschwil, 10. Oktober 2024 Basilea Pharmaceutica...

Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis

Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX:...

Basilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanogepix bei Candidämie und invasiver Candidiasis

Basilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanogepix bei Candidämie und invasiver Candidiasis Allschwil, 24. September 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN...

Basilea schliesst Vereinbarung mit BARDA zur Entwicklung neuartiger Medikamente für die Behandlung von Infektionen durch Pilze und Bakterien ab und erhält erste Förderung

Basilea schliesst Vereinbarung mit BARDA zur Entwicklung neuartiger Medikamente für die Behandlung von Infektionen durch Pilze und Bakterien ab und erhält erste Förderung Bereitstellung eines...

Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding

Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding Initial funding of USD 29 million to support development of Basilea’s clinical...

Starke Cresemba® (Isavuconazol)-Verkäufe in Europa lösen USD 25 Mio. Umsatzmeilensteinzahlung an Basilea aus

Starke Cresemba® (Isavuconazol)-Verkäufe in Europa lösen USD 25 Mio. Umsatzmeilensteinzahlung an Basilea aus Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 6. September 2024 Basilea...

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September...

European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea

European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea Ad hoc...

Entscheidung der Europäischen Kommission zur Zulassung von Antipilzmittel Cresemba® (Isavuconazol) bei Kindern und Verlängerung der Marktexklusivität löst CHF 10 Mio. Meilensteinzahlung an Basilea aus

Entscheidung der Europäischen Kommission zur Zulassung von Antipilzmittel Cresemba® (Isavuconazol) bei Kindern und Verlängerung der Marktexklusivität löst CHF 10 Mio. Meilensteinzahlung an Basilea...

기간	시가	고가	저가	평균 일일 거래량	VWAP
1	46.2	46.2	46.2	24772	46.2	DE
4	46.2	46.2	46.2	6450	46.2	DE
12	46.2	46.2	46.2	2720	46.2	DE
26	46.2	46.2	46.2	1894	46.2	DE
52	46.2	46.2	46.2	2369	46.2	DE
156	46.2	46.2	46.2	4234	46.2	DE
260	46.2	46.2	46.2	3929	46.2	DE

가장 활성
% 상승자
% 패자

기호	가격	볼륨
PPSProton Motor Power Systems Plc	0.55p (83.33%)	5.86M
CADCadogan Energy Solutions Plc	4.25p (77.08%)	14.62M
KZGKazera Global Plc	1.525p (35.56%)	89.49M
WEBWebis Holdings Plc	0.125p (19.05%)	4.67M
PETPetrel Resources Plc	1.35p (17.39%)	1.43M
MILAMila Resources Plc	0.35p (-30.00%)	33.37M
IPXImpax Asset Management Group Plc	250.00p (-23.66%)	3.14M
RNEPEcofin U.s. Renewables Infrastructure Trust Plc	26.20p (-19.88%)	21.5k
PMPPortmeirion Group Plc	174.00p (-15.12%)	58.93k
ROCKRockfire Resources Plc	0.165p (-13.16%)	190.11M
NTVONativo Resources Plc	0.0024p (0.00%)	967.12M
TRPTower Resources Plc	0.027p (1.89%)	481.24M
VRSVersarien Plc	0.034p (11.48%)	374.02M
ORCPOracle Power Plc	0.0315p (-11.27%)	305M
CPXCap-xx Limited	0.145p (0.00%)	260.82M